Decreased acid suppression therapy overuse after education and medication reconciliation

International Journal of Clinical Practice

Volumn 67, Issue 1, 2013, Pages 60-65

  Gupta, R ^a,b   Marshall, J ^b   Munoz, J C ^a   Kottoor, R ^a   Jamal, M M ^c   Vega, K J ^a,d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b University of Missouri   (United States)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIULCER AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STEROID;

ACID SUPPRESSION THERAPY; ADULT; ANTICOAGULATION; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DRUG USE; DRUG UTILIZATION; DYSPEPSIA; ENDOCRINE DISEASE; ETHNICITY; FEMALE; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL MANAGEMENT; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; PATIENT CARE; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; STRESS ULCER; THROMBOCYTE COUNT; ULCER;

ANTACIDS; DRUG UTILIZATION REVIEW; FEMALE; FLORIDA; HEALTH SERVICES MISUSE; HOSPITALIZATION; HUMANS; INSERVICE TRAINING; MALE; MEDICAL RECORDS; MEDICAL STAFF, HOSPITAL; MIDDLE AGED; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 84871407332     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12046     Document Type: Article

References (30)

1. Gupta R, Garg P, Kottoor R, et al., Overuse of acid suppression therapy in hospitalized patients. South Med J 2010; 103: 207-11.
2. Zink DA, Pohlman M, Barnes M, et al., Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther 2005; 21: 1203-9.
3. Parente F, Cucino C, Gallus S, et al., Hospital use of acid suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther 2003; 17: 1503-6.
4. Ben-Menachem T, Fogel R, Patel RV, et al., Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med 1994; 121: 568-75.
5. American Society of Health System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm 1999; 56: 347-79.
6. Cash BD,. Evidence based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med 2002; 30: s373-8.
7. Aciphex® Prescribing Information. Eisai Inc., 2009.
8. Nexium® Prescribing Information. AstraZeneca, 2009.
9. Prevacid® Prescribing Information. Takeda Pharmaceuticals, Inc., 2009.
10. Prilosec® Prescribing Information. AstraZeneca, 2008.
11. Protonix® Prescribing Information. Wyeth Pharmaceuticals, Inc., 2008.
12. Zegerid™ Prescribing Information. Santarus, Inc., 2008.
13. Cook DJ, Reeve BK, Guyatt GH, et al., Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta- analyses. JAMA 1996; 275: 308-14.
14. Gardner TB, Robertson DJ,. Stress ulcer prophylaxis in non-critically ill patients: less may be more. Am J Gastroenterol 2006; 61: 873-8.
15. Welage LS,. Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health Syst Pharm 2005; 62: 4-10.
16. Chong E, Ensom MHH,. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71.
17. Reilly JP,. Safety profile of the proton pump inhibitors. Am J Health Syst Pharm 1999; 56: S11-7.
18. Franko TG, Richter JE,. Proton pump inhibitors for gastric acid related diseases. Cleve Clin J Med 1998; 65: 27-34.
19. Humphries TJ, Merritt GJ,. Review article. Drug interactions with agents used to treat acid related diseases. Aliment Pharmacol Ther 1999; 13: 18-26.
20. Termanini P, Gibril F, Stuliff VE, et al., Effect of long term gastric acid suppressive therapy on serum Vit B12 levels in patients with Zollinger Ellison Syndrome. Am J Med 1998; 104: 422-30.
21. O'Connell MB, Madden DM, Murray AM, et al., Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778-81.
22. Chen J, Yuan YC, Leontiadis GI, et al., Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012; 46: 93-114.
23. Heidelbaugh JJ, Inadomi JM,. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non- ICU hospitalized patients. Am J Gastroenterol 2006; 101: 2200-5.
24. Welage LS, Berardi RR,. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid related diseases. J Am Pharm Assoc 2000; 40: 52-62.
25. Dial S, Alrasadi K, Manoukian C, et al., Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case control studies. Can Med Assoc 2004; 171: 33-8.
26. Laheij R, Sturkenboom M, Hsaaings RJ, et al., Risk of community acquired pneumonia and use of gastric acid suppressive drugs. JAMA 2004; 292: 1955-60.
27. Leonard J, Marshall JK, Moayyedi P,. Systematic review of the risk of enteric infection in patient taking acid suppression. Am J Gastroenterol 2007; 102: 2047-205.
28. Mostafa G, Sing RF, Matthews BD, et al., The economic benefit of practice guidelines for stress ulcer prophylaxis. Am Surg 2002; 68: 146-50.
29. Pallarito K,. How safe are popular reflux drugs? Experts debate evidence linking acid- blockers to possible bone, heart problems. US News World Rep November 4, 2009, http://health.usnews.com/health-news/family-health/bones- joints-and-muscles/articles/2009/11/04/how-safe-are-popular-reflux-drugs (accessed 22 March 2012)
30. Jick H, Wilson P, Wiggins P, et al., Comparison of prescription drug costs in the United States and the United Kingdom, part 2: proton pump inhibitors. Pharmacotherapy 2012; 32: 489-92.